Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BROOKLYN IMMUNOTHERAPEUTICS, INC.

(BTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer

09/22/2021 | 10:08am EDT

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Roger Sidhu, M.D. as its Chief Medical Officer, effective September 20, 2021.

“Roger’s extensive R&D experience, including many years in late-stage clinical development involving a wide array of treatment modalities for hematologic malignancies and solid tumors, brings him to Brooklyn at an inflection point where his insight and understanding will help guide us to the next stage of our company’s development,” commented Howard J. Federoff, M.D., Ph.D., Brooklyn’s CEO and President. “We welcome Roger and look forward to collaborating with him in working to transform the way our targeted diseases are treated.”

“Brooklyn ImmunoTherapeutics’ cutting-edge mRNA-based gene editing and cellular reprogramming platform positions the company at the forefront of an emerging personalized medicine revolution, and I look forward to having a guiding hand in driving the company forward as a leader in the field,” added Dr. Sidhu.

Prior to joining Brooklyn, Dr. Sidhu served as Vice President, Clinical Development at Kite Pharma, a subsidiary of Gilead Sciences. Previously, he held key positions at Roivant Sciences, where he was Chief Medical Officer and Executive Vice President and Head of Research and Development, Cell Design Labs, where he served as Chief Medical Officer, and Amgen, where he served as Global Product General Manager, Translational Sciences. Dr. Sidhu is a Fellow of the Royal College of Physicians and Surgeons of Canada in both internal medicine and medical oncology. He earned a Bachelor of Science (Biochemistry) from University of Alberta, and his M.D. from Queen’s University, Kingston, Ontario, where he also did his residency.

About Brooklyn ImmunoTherapeutics
Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases.

Brooklyn’s most advanced program is IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

Brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.

Investor Relations Contact:
CORE IR
516-222-2560
investors@brooklynitx.com

Media Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com


Primary Logo


ę GlobeNewswire 2021
All news about BROOKLYN IMMUNOTHERAPEUTICS, INC.
10/15BROOKLYN IMMUNOTHERAPEUTICS : to Transfer Share Listing to Nasdaq From NYSE American
MT
10/14BROOKLYN IMMUNOTHERAPEUTICS : to Move Stock Exchange Listing to Nasdaq - Form 8-K
PU
10/14BROOKLYN IMMUNOTHERAPEUTICS : to Move Stock Exchange Listing to Nasdaq
AQ
10/06BROOKLYN IMMUNOTHERAPEUTICS : Maxim Starts Brooklyn ImmunoTherapeutics at Buy with $20 Pri..
MT
09/23BROOKLYN IMMUNOTHERAPEUTICS : Provides Highlights of Shareholder Update Call from Septembe..
PU
09/23Brooklyn ImmunoTherapeutics ReportsáInducement Grants
GL
09/22BROOKLYN IMMUNOTHERAPEUTICS : Names Roger Sidhu Chief Medical Officer
MT
09/22BROOKLYN IMMUNOTHERAPEUTICS : Provides Highlights of Shareholder Update
AQ
09/22Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer
GL
09/22Brooklyn ImmunoTherapeutics, Inc. Appoints Roger Sidhu as Chief Medical Officer
CI
More news
Analyst Recommendations on BROOKLYN IMMUNOTHERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2020
Net income 2020
Net Debt 2020
P/E ratio 2020
Yield 2020
Capitalization 473 M 473 M -
EV / Sales 2020
Capi. / Sales 2021 -
Nbr of Employees 10
Free-Float 46,9%
Chart BROOKLYN IMMUNOTHERAPEUTICS, INC.
Duration : Period :
Brooklyn ImmunoTherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BROOKLYN IMMUNOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 9,15 $
Average target price 20,00 $
Spread / Average Target 119%
EPS Revisions
Managers and Directors
Howard J. Federoff President, Chief Executive Officer & Director
Sandra Gurrola Chief Financial Officers
Charles R. Cherington Chairman
Kevin A. D'Amour Chief Scientific Officer
Jay Sial Chief Administrative & Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
BROOKLYN IMMUNOTHERAPEUTICS, INC.104.24%473
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414